Search Clinical Trials

Clinical Trials Search Results

The results of your search are listed below. To view the details of a trial or study, click on the see details >> link. Or start a new search.

Searched for: Chronic Lymphoid Leukemia (CLL)

12 results total

Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial

See details >>

Principal Investigator: Mohamed Sorror, MD, MSc

Study Number: 1840.00

A Phase II Study of Fludarabine (F), Rituximab (R) and Avastin (A) Followed by RA Maintenance Therapy in Patients with Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)

See details >>

Principal Investigator: John Pagel, MD, PhD

Study Number: 2278.00

A Study of 131I-Tositumomab (Bexxar®) Consolidation in Patients with B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

See details >>

Principal Investigator: John Pagel, MD, PhD

Study Number: PSOC 2301

A Multi-Center Phase III Study Comparing Nonmyeloablative Conditioning with TBI versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies

See details >>

Principal Investigator: Brenda Sandmaier, MD

Study Number: 1813.00

A Multi-Center Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil

See details >>

Principal Investigator: David Maloney, MD, PhD

Study Number: 1898.00

A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial

See details >>

Principal Investigator: Brenda Sandmaier, MD

Study Number: 1938.00

Campath® (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies: a Multicenter Trial

See details >>

Principal Investigator: Brenda Sandmaier, MD

Study Number: 1959.00

A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation

See details >>

Principal Investigator: Monica Thakar, MD

Study Number: 2230.00

Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen

See details >>

Principal Investigator: Colleen Delaney, MD, MSc

Study Number: 2239.00

A Phase I / ll Trial of Fenretinide (4-HPR) + Rituximab in Patients with B-Cell Lymphoma

See details >>

Principal Investigator: Ajay Gopal, MD

Study Number: 6071

Displaying first 10 of 12 total results. Click to view all 12 results.

Search Options

Select a disease from the list below:

Limit results to studies enrolling:
Both Adults & Pediatrics Adults Pediatrics

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.